Epithelial Cell Death Analysis of Cell Cycle by Flow Cytometry White Paper
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Restoring MLL Reactivates Latent Tumor Suppression-Mediated Vulnerability to Proteasome Inhibitors
Oncogene (2020) 39:5888–5901 https://doi.org/10.1038/s41388-020-01408-7 ARTICLE Restoring MLL reactivates latent tumor suppression-mediated vulnerability to proteasome inhibitors 1 1 2 1 3 1 4 2 Maolin Ge ● Dan Li ● Zhi Qiao ● Yan Sun ● Ting Kang ● Shouhai Zhu ● Shifen Wang ● Hua Xiao ● 1 5 4 1 Chunjun Zhao ● Shuhong Shen ● Zhenshu Xu ● Han Liu Received: 12 March 2020 / Revised: 16 July 2020 / Accepted: 23 July 2020 / Published online: 30 July 2020 © The Author(s) 2020. This article is published with open access Abstract MLL undergoes multiple distinct chromosomal translocations to yield aggressive leukemia with dismal outcomes. Besides their well-established role in leukemogenesis, MLL fusions also possess latent tumor-suppressive activity, which can be exploited as effective cancer treatment strategies using pharmacological means such as proteasome inhibitors (PIs). Here, using MLL-rearranged xenografts and MLL leukemic cells as models, we show that wild-type MLL is indispensable for the latent tumor-suppressive activity of MLL fusions. MLL dysfunction, shown as loss of the chromatin accumulation and subsequent degradation of MLL, compromises the latent tumor suppression of MLL-AF4 and is instrumental for the 1234567890();,: 1234567890();,: acquired PI resistance. Mechanistically, MLL dysfunction is caused by chronic PI treatment-induced epigenetic reprogramming through the H2Bub-ASH2L-MLL axis and can be specifically restored by histone deacetylase (HDAC) inhibitors, which induce histone acetylation and recruits MLL on chromatin to promote cell cycle gene expression. Our findings not only demonstrate the mechanism underlying the inevitable acquisition of PI resistance in MLL leukemic cells, but also illustrate that preventing the emergence of PI-resistant cells constitutes a novel rationale for combination therapy with PIs and HDAC inhibitors in MLL leukemias. -
DNA Damage Checkpoint Dynamics Drive Cell Cycle Phase Transitions
bioRxiv preprint doi: https://doi.org/10.1101/137307; this version posted August 4, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. DNA damage checkpoint dynamics drive cell cycle phase transitions Hui Xiao Chao1,2, Cere E. Poovey1, Ashley A. Privette1, Gavin D. Grant3,4, Hui Yan Chao1, Jeanette G. Cook3,4, and Jeremy E. Purvis1,2,4,† 1Department of Genetics 2Curriculum for Bioinformatics and Computational Biology 3Department of Biochemistry and Biophysics 4Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill 120 Mason Farm Road Chapel Hill, NC 27599-7264 †Corresponding Author: Jeremy Purvis Genetic Medicine Building 5061, CB#7264 120 Mason Farm Road Chapel Hill, NC 27599-7264 [email protected] ABSTRACT DNA damage checkpoints are cellular mechanisms that protect the integrity of the genome during cell cycle progression. In response to genotoxic stress, these checkpoints halt cell cycle progression until the damage is repaired, allowing cells enough time to recover from damage before resuming normal proliferation. Here, we investigate the temporal dynamics of DNA damage checkpoints in individual proliferating cells by observing cell cycle phase transitions following acute DNA damage. We find that in gap phases (G1 and G2), DNA damage triggers an abrupt halt to cell cycle progression in which the duration of arrest correlates with the severity of damage. However, cells that have already progressed beyond a proposed “commitment point” within a given cell cycle phase readily transition to the next phase, revealing a relaxation of checkpoint stringency during later stages of certain cell cycle phases. -
Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and Its
Published OnlineFirst January 21, 2015; DOI: 10.1158/1078-0432.CCR-14-1950 Biology of Human Tumors Clinical Cancer Research Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and Its Nuclear Accumulation Suppresses Gastric Tumorigenesis Longlong Cao1,2, Jiechao Zhou2, Junrong Zhang1,2, Sijin Wu3, Xintao Yang1,2, Xin Zhao2, Huifang Li2, Ming Luo1, Qian Yu1, Guangtan Lin1, Huizhong Lin1, Jianwei Xie1, Ping Li1, Xiaoqing Hu3, Chaohui Zheng1, Guojun Bu2, Yun-wu Zhang2,4, Huaxi Xu2,4,5, Yongliang Yang3, Changming Huang1, and Jie Zhang2,4 Abstract Purpose: As a cyclin-independent atypical CDK, the role of correlated with the severity of gastric cancer based on tumor CDK5 in regulating cell proliferation in gastric cancer remains and lymph node metastasis and patient 5-year fatality rate. unknown. Nuclear localization of CDK5 was found to be significantly Experimental Design: Expression of CDK5 in gastric tumor decreased in tumor tissues and gastric cancer cell lines, and paired adjacent noncancerous tissues from 437 patients was whereas exogenously expression of nucleus-targeted CDK5 measured by Western blotting, immunohistochemistry, and real- inhibited the proliferation and xenograft implantation of time PCR. The subcellular translocation of CDK5 was monitored gastric cancer cells. Treatment with the small molecule during gastric cancer cell proliferation. The role of nuclear CDK5 NS-0011, which increases CDK5 accumulation in the nucleus, in gastric cancer tumorigenic proliferation and ex vivo xenografts suppressed both cancer cell proliferation and xenograft was explored. Furthermore, by screening for compounds in the tumorigenesis. PubChem database that disrupt CDK5 association with its nu- Conclusions: Our results suggest that low CDK5 expression is clear export facilitator, we identified a small molecular (NS-0011) associated with poor overall survival in patients with gastric that inhibits gastric cancer cell growth. -
Cyclin-Dependent Kinases and P53 Pathways Are Activated Independently and Mediate Bax Activation in Neurons After DNA Damage
The Journal of Neuroscience, July 15, 2001, 21(14):5017–5026 Cyclin-Dependent Kinases and P53 Pathways Are Activated Independently and Mediate Bax Activation in Neurons after DNA Damage Erick J. Morris,1 Elizabeth Keramaris,2 Hardy J. Rideout,3 Ruth S. Slack,2 Nicholas J. Dyson,1 Leonidas Stefanis,3 and David S. Park2 1Massachusetts General Hospital Cancer Center, Laboratory of Molecular Oncology, Charlestown, Massachusetts 02129, 2Neuroscience Research Institute, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada, and 3Columbia University, New York, New York 10032 DNA damage has been implicated as one important initiator of ization, and DNA binding that result from DNA damage are not cell death in neuropathological conditions such as stroke. Ac- affected by the inhibition of CDK activity. Conversely, no de- cordingly, it is important to understand the signaling processes crease in retinoblastoma protein (pRb) phosphorylation was that control neuronal death induced by this stimulus. Previous observed in p53-deficient neurons that were treated with camp- evidence has shown that the death of embryonic cortical neu- tothecin. However, either p53 deficiency or the inhibition of rons treated with the DNA-damaging agent camptothecin is CDK activity alone inhibited Bax translocation, cytochrome c dependent on the tumor suppressor p53 and cyclin-dependent release, and caspase-3-like activation. Taken together, our re- kinase (CDK) activity and that the inhibition of either pathway sults indicate that p53 and CDK are activated independently alone leads to enhanced and prolonged survival. We presently and then act in concert to control Bax-mediated apoptosis. show that p53 and CDKs are activated independently on par- allel pathways. -
Caspase-Dependent Activation of Cyclin-Dependent Kinases During Fas-Induced Apoptosis in Jurkat Cells
Proc. Natl. Acad. Sci. USA Vol. 95, pp. 6785–6790, June 1998 Cell Biology Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells BIN-BING ZHOU,HONGLIN LI,JUNYING YUAN, AND MARC W. KIRSCHNER Department of Cell Biology, Harvard Medical School, Boston, MA 02115 Contributed by Marc W. Kirschner, April 7, 1998 ABSTRACT The activation of cyclin-dependent kinases To study the mechanism of cdc2 and cdk2 activation in (cdks) has been implicated in apoptosis induced by various apoptotic cells, we examined cyclin synthesis, cyclin degrada- stimuli. We find that the Fas-induced activation of cdc2 and tion, and posttranslational modifications of cdc2 and cdk2 cdk2 in Jurkat cells is not dependent on protein synthesis, during Fas-induced apoptosis in Jurkat cells. We find that Fas which is shut down very early during apoptosis before induction activates cdc2 and cdk2, despite a potential loss of caspase-3 activation. Instead, activation of these kinases these proteins caused by the very rapid drop in the capacity for seems to result from both a rapid cleavage of Wee1 (an protein synthesis. Activation of these kinases seems to result inhibitory kinase of cdc2 and cdk2) and inactivation of from the maintenance of cyclin levels by rapid inactivation of anaphase-promoting complex (the specific system for cyclin APC, through a caspase-dependent cleavage of one of its degradation), in which CDC27 homolog is cleaved during subunits, and tyrosine dephosphorylation of cdks caused by a apoptosis. Both Wee1 and CDC27 are shown to be substrates cleavage of the inhibitory kinase Wee1. -
Transcriptional Regulation of the P16 Tumor Suppressor Gene
ANTICANCER RESEARCH 35: 4397-4402 (2015) Review Transcriptional Regulation of the p16 Tumor Suppressor Gene YOJIRO KOTAKE, MADOKA NAEMURA, CHIHIRO MURASAKI, YASUTOSHI INOUE and HARUNA OKAMOTO Department of Biological and Environmental Chemistry, Faculty of Humanity-Oriented Science and Engineering, Kinki University, Fukuoka, Japan Abstract. The p16 tumor suppressor gene encodes a specifically bind to and inhibit the activity of cyclin-CDK specific inhibitor of cyclin-dependent kinase (CDK) 4 and 6 complexes, thus preventing G1-to-S progression (4, 5). and is found altered in a wide range of human cancers. p16 Among these CKIs, p16 plays a pivotal role in the regulation plays a pivotal role in tumor suppressor networks through of cellular senescence through inhibition of CDK4/6 activity inducing cellular senescence that acts as a barrier to (6, 7). Cellular senescence acts as a barrier to oncogenic cellular transformation by oncogenic signals. p16 protein is transformation induced by oncogenic signals, such as relatively stable and its expression is primary regulated by activating RAS mutations, and is achieved by accumulation transcriptional control. Polycomb group (PcG) proteins of p16 (Figure 1) (8-10). The loss of p16 function is, associate with the p16 locus in a long non-coding RNA, therefore, thought to lead to carcinogenesis. Indeed, many ANRIL-dependent manner, leading to repression of p16 studies have shown that the p16 gene is frequently mutated transcription. YB1, a transcription factor, also represses the or silenced in various human cancers (11-14). p16 transcription through direct association with its Although many studies have led to a deeper understanding promoter region. -
P14arf Induces G2 Arrest and Apoptosis Independently of P53
Oncogene (2003) 22, 1822–1835 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc ARF p14 induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice Be´ atrice Eymin, Camille Leduc, Jean-Luc Coll, Elisabeth Brambilla and Sylvie Gazzeri Groupe de Recherche sur le Cancer du Poumon, EA 2021, Equipe INSERM 9924, Institut Albert Bonniot, 38706 La Tronche Cedex, France Until recently, the ability of ARF (human p14ARF, murine kinases (Serrano et al., 1993). On the other hand, ARF p19ARF) tumour-suppressor protein, encoded by the protects against cellular transformation and immortali- INK4A/ARF locus, to inhibit cell growth in response to zation by activating the p53tumour suppressive protein various stimuli was related to its ability to stabilize p53 (Sherr, 1998). Expression of ARF is induced in response through the so-called ARF/MDM2/p53 pathway. How- to activated oncogenes such as Ras (Serrano et al., 1997; ever, recent data have demonstrated that ARF is not Palmero et al., 1998), c-myc (Zindy et al., 1998), E1A (de implicated in this unique p53-dependent pathway. By use Stanchina et al., 1998), Abl (Radfar et al., 1998; Cong of transient and stable expression, we show here that et al., 1999) and E2F-1 (Bates et al., 1998; Dimri et al., human p14ARF inhibits the growth of human tumoral cells 2000) as well as during replicative senescence (Sherr, lacking functional p53 by inducing a transient G2 arrest 1998). Since ARF-null mice are highly tumour prone ARF and subsequently apoptosis. -
Recruitment of Leukemic Cells from G 0 Phase of the Cell Cycle By
Leukemia (2003) 17, 2049–2059 & 2003 Nature Publishing Group All rights reserved 0887-6924/03 $25.00 www.nature.com/leu CORRESPONDENCE Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin Leukemia (2003) 17, 2049–2051. doi:10.1038/sj.leu.2403085 were not affected by daunorubicin-induced cell death. To analyze whether a similar cell cycle-specific sensitivity to Ara-C TO THE EDITOR and daunorubicin was observed in other leukemic cell lines, we analyzed four acute lymphoblastic leukemia cell lines and one Although the majority of patients with acute myeloid leukemia CML blast crisis cell line, which were generated in our (AML) responds to initial treatment, relapse of the disease occurs laboratory by culturing of leukemic blasts from five different in a significant percentage of these patients.1 The cell cycle patients in serum-free medium at high cell concentrations until status of leukemic cells may play an important role in the spontaneous sustained proliferation of the leukemic cells response to treatment of leukemic cells. Especially, the broadly occurred. These cell lines cytogenetically and phenotypically used cytotoxic agent Cytarabine (Ara-C) has been demonstrated resembled the primary leukemia. Figure 1b shows the median to exert its action via intercalation into the DNA of cells cell cycle distribution within these cell lines after incubation for À6 specifically in the S phase of the cell cycle, and sensitivity to this 48 h in medium alone, or in medium containing 1 Â 10 M Ara- agent is therefore described to be specific for cells in active cell C or daunorubicin. -
Cell Cycle Profile Using the Cellometer Vision Image Cytometer
Measuring Drug Effect on Cell Cycle Profile Using the Cellometer Vision Image Cytometer Nexcelom Bioscience LLC. | 360 Merrimack Street, Building 9 | Lawrence, MA 01843 T: 978.327.5340 | F: 978.327.5341 | E: [email protected] | www.nexcelom.com 1001276 Rev. A Measuring Drug Effect on Cell Cycle Profile Using the Cellometer Vision Image Cytometer Introduction Cell cycle analysis is a commonly used assay in both clinical diagnosis and biomedical research. This analysis distinguishes cells in different phases of cell cycle and is often used to determine cellular response to drugs and biological stimulations [1, 2]. Because this assay is based on measuring the DNA content in a cell population, it can also be used to analyze DNA fragmentation during apoptosis, requiring multicolor fluorescent staining of biomarkers and DNA [3]. Recently, a small desktop imaging cytometry system (Cellometer Vision) has been developed by Nexcelom Bioscience LLC for automated cell concentration and viability measurement using bright-field (BR) and fluorescent (FL) imaging methods [4]. The system can perform rapid cell enumeration using disposable counting slides. The software utilizes a novel counting algorithm for accurate and consistent measurement of cell concentration and viability on a variety of cell types [5]. By developing fluorescent-based cell cycle assays, the Cellometer imaging cytometry can provide a quick, simple, and inexpensive alternative for biomedical research, which may be beneficial for smaller research laboratories and clinics. In this work, we demonstrate new applications of the Cellometer Vision for fluorescence- based cell population analysis as an alternative for flow cytometry. Cell cycle analysis was performed by inducing specific arrest in G0/G1, S, and G2/M phase of Jurkat cell population with aphidicolin, etoposide, and nocodazole, respectively [6-8]. -
P53 Phosphorylation and Association with Murine Double Minute 2, C-Jun
[CANCER RESEARCH 60, 896–900, February 15, 2000] Advances in Brief p53 Phosphorylation and Association with Murine Double Minute 2, c-Jun ARF NH2-Terminal Kinase, p14 , and p300/CBP during the Cell Cycle and after Exposure to Ultraviolet Irradiation1 Thomas Buschmann, Victor Adler, Ekaterina Matusevich, Serge Y. Fuchs, and Ze’ev Ronai2 Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, New York 10029 Abstract though the mechanisms underlying the ability of p53 to elicit such opposing effects are yet to be identified, independent studies point to p53 phosphorylation and association with proteins is implicated in its a different set of p53 regulators and effectors that are affected by p53 stability and activity. We have compared the association of DNA-bound in each of these scenarios. and overall pools of p53 with murine double minute 2 (Mdm2), c-Jun NH -terminal kinase (JNK), p300/CBP, and p14ARF during cell cycle In studying the regulation of p53 stability, we demonstrated previ- 2 ously that, in Swiss 3T3 cells, JNK and Mdm2 target p53 degradation progression. Whereas DNA-bound p53 associates with JNK at G0-G1 and in different phases of the cell cycle (7). In this study, we have with Mdm2 and p300 during S and G2-M phases, the general pool of p53 was found in complex with JNK and Mdm2 almost throughout the cell compared the association of subpopulations of p53 with proteins cycle. Phosphorylation of p53 at serines 9, 15, and 20 is at the highest levels implicated in stability and activity of p53 and monitored the pattern of at G1 and at serines 37 and 392 during G2-M phase. -
Correction1 4784..4785
Correction Correction: PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis In the article on PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis published in the May 15, 2009 issue of Clinical Cancer Research, there was an error in Table 1. Down-regulated genes were incorrectly labeled as up-regulated genes. The correct table appears here. Bhalla S, Balasubramanian S, David K, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-nB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 2009;15:3354–65. Table 1. Selected genes from expression analysis following 24-h treatment with PCI-24781, bortezomib, or the combination (in Ramos cells) Accn # Down-regulated genes 0.25 Mmol/L PCI/3 nmol/L Bor Name PCI-24781 Bortezomib Combination* Cell cycle-related NM_000075 Cyclin-dependent kinase 4 (CDK4) 0.49 0.83 0.37 NM_001237 Cyclin A2 (CCNA2) 0.43 0.87 0.37 NM_001950 E2F transcription factor 4, p107/p130-binding (E2F4) 0.48 0.79 0.40 NM_001951 E2F transcription factor 5, p130-binding (E2F5) 0.46 0.98 0.43 NM_003903 CDC16 cell division cycle 16 homolog (S cerevisiae) (CDC16) 0.61 0.78 0.43 NM_031966 Cyclin B1 (CCNB1) 0.55 0.90 0.43 NM_001760 Cyclin D3 (CCND3) 0.48 1.02 0.46 NM_001255 CDC20 cell division cycle 20 homolog (S cerevisiae; CDC20) 0.61 0.82 0.46 NM_001262 Cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4; CDKN2C) 0.61 1.15 0.56 NM_001238 Cyclin E1 (CCNE1) 0.56 1.05 0.60 NM_001239 Cyclin H (CCNH) 0.74 0.90 0.64 NM_004701 -
Introduction to DNA Cell Cycle Analysis
INTRODUCTION TO CELL CYCLE ANALYSIS Written by Dr. Peter Rabinovitch, M.D., Ph.D. Published by Phoenix Flow Systems, Inc. 6790 Top Gun St. #1 San Diego, CA. USA 92121 858 453-5095 fax 858 453-2117 The Biological Cell Cycle .........................2 DNA Analysis and the Flow Cytometric Cell Cycle ....................3 Diploid and Aneuploid DNA Contents......5 Cell Cycle Analysis of DNA Content Histograms.........................6 Fitting of Background “Debris” and Effects of Nucleus Sectioning..................9 Fitting and Correction for the Effects of Cellular or Nuclear Aggregation.........16 Quantitation of Background, Aggregates And Debris.....................................................31 Analysis of Apoptosis.............................31 Beyond Single Parameter Analysis: DNA vs. Immunofluorescence................32 Basics of DNA Cell Cycle Analysis www.phoenixflow.com Page 1 This chapter is organized into progressively more advanced sections. Feel free to skip ahead to the level appropriate for your background. THE BIOLOGICAL CELL CYCLE Reproduction of cells requires cell division, with production of two daughter cells. The most obvious cellular structure that requires duplication and division into daughter cells is the cell nucleus - the repository of the cell's genetic material, DNA. With few exceptions each cell in an organism contains the same amount of DNA and the same complement of chromosomes. Thus, cells must duplicate their allotment of DNA prior to division so that each daughter will receive the same DNA content as the parent. The cycle of increase in components (growth) and division, followed by growth and division of these daughter cells, etc., is called the cell cycle. The two most obvious features of the cell cycle are the synthesis and duplication of nuclear DNA before division, and the process of cellular division itself - mitosis.